New developments and opportunities in oral mucosal drug delivery for local and systemic disease

Advanced Drug Delivery Reviews

Volumn 64, Issue 1, 2012, Pages 16-28

  Hearnden, Vanessa ^a,b   Sankar, Vidya ^c   Hull, Katrusha ^d   Juras, Danica Vidović ^e,f   Greenberg, Martin ^g   Kerr, A Ross ^h   Lockhart, Peter B ⁱ   Patton, Lauren L ^j   Porter, Stephen ^k   Thornhill, Martin H ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d WESTMEAD HOSPITAL   (Australia)

^e UNIVERSITY OF ZAGREB   (Croatia)

^f UNIVERSITY OF ZAGREB   (Croatia)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

ⁱ CAROLINAS MEDICAL CENTER   (United States)

^j UNIVERSITY OF NORTH CAROLINA   (United States)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Drug delivery technology; Formulations; Local drug delivery; Mucoadhesives; Oral mucosa; Polymersomes; Targeting; Trans mucosal

Indexed keywords

FORMULATIONS; LOCAL DRUG DELIVERY; MUCOADHESIVES; ORAL MUCOSA; POLYMERSOMES; TARGETING; TRANS-MUCOSAL;

GENE THERAPY;

DRUG DELIVERY;

COTRIMOXAZOLE; ENZYME INHIBITOR; MICONAZOLE; MOUTHWASH; NANOPARTICLE; TRIAMCINOLONE;

CANDIDIASIS; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TARGETING; ENZYME PRODRUG THERAPY; GEL; GENE THERAPY; GENE VECTOR; HUMAN; LIPOSOMAL DELIVERY; MEMBRANE PERMEABILITY; MUCOADHESION; ORAL SPRAY; PASTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; THRUSH; TRANSDERMAL PATCH;

ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; MOUTH MUCOSA; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84858441488     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.02.008     Document Type: Review

References (128)

1. Nicolazzo J.A., Reed B.L., Finnin B.C. Enhancing the buccal mucosal uptake and retention of triamcinolone acetonide. J. Control. Release 2005, 105:240-248.
2. Prausnitz M.R., Langer R. Transdermal drug delivery. Nat. Biotechnol. 2008, 26:1261-1268.
3. Galey W.R., Londsdale H.K., Nacht S. The in vitro permeability of skin and buccal mucosa to selected drugs and tritiated water. J. Invest. Dermatol. 1976, 67:713-717.
4. Burkman R.T. Transdermal hormonal contraception: benefits and risks. Am. J. Obstet. Gynecol. 2007, 197:134.e131-134.e136.
5. Gore A.V., Chien Y.W. The nicotine transdermal system. Clin. Dermatol. 1998, 16:599-615.
6. Park I., Kim D., Song J., In C., Jeong S.-W., Lee S., Min B., Lee D., Kim S.-O. Buprederm™, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies. Pharm. Res. 2008, 25:1052-1062.
7. Bukstein O.G. Transdermal methylphenidate system: old wine in a new bottle. Expert Opin. Drug Metab. Toxicol. 2009, 5:661-665.
8. Galer B.S., Rowbotham M.C., Perander J., Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999, 80:533-538.
9. Nachum Z., Shupak A., Gordon C.R. Transdermal scopolamine for prevention of motion sickness: clinical pharmacokinetics and therapeutic applications. Clin. Pharmacokinet. 2006, 45:543-566.
10. Dixit N., Bali V., Baboota S., Ahuja A., Ali J. Iontophoresis - an approach for controlled drug delivery: a review. Curr. Drug Deliv. 2007, 4:1-10.
11. Stead L.F., Perera R., Bullen C., Mant D., Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2008, 23:CD000146.
12. Silverman S.L. Calcitonin. Am. J. Med. Sci. 1997, 313:13-16.
13. Rose E.H., Aledort L.M. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann. Intern. Med. 1991, 114:563-568.
14. Behl C.R., Pimplaskar H.K., Sileno A.P., deMeireles J., Romeo V.D. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Deliv. Rev. 1998, 29:89-116.
15. Ugwoke M.I., Verbeke N., Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 2001, 53:3-22.
16. Shojaei A.H. Buccal mucosa as a route for systemic drug delivery: a review. J. Pharm. Pharm. Sci. 1998, 1:15-30.
17. Sankar V., Hearnden V., Hull K., Juras D.V., Greenberg M., Kerr A.R., Lockhart P.B., Patton L.L., Porter S., Thornhill M. Local drug delivery for oral mucosal diseases: challenges and opportunities. Oral Dis. 2011, 17(Suppl. I):73-84.
18. Shimono M., Clementi F. Intercellular junctions of oral epithelium. I. Studies with freeze-fracture and tracing methods of normal rat keratinized oral epithelium. J. Ultrastruct. Res. 1976, 56:121-136.
19. Salamat-Miller N., Chittchang M., Johnston T.P. The use of mucoadhesive polymers in buccal drug delivery. Adv. Drug Deliv. Rev. 2005, 57:1666-1691.
20. Kulkarni U., Mahalingam R., Pather S.I., Li X., Jasti B. Porcine buccal mucosa as an in vitro model: relative contribution of epithelium and connective tissue as permeability barriers. J. Pharm. Sci. 2009, 98:471-483.
21. Ganem-Quintanar A., Falson-Rieg F., Buri P. Contribution of lipid components to the permeability barrier of oral mucosa. Eur. J. Pharm. Biopharm. 1997, 44:107-120.
22. Squier C.A., Hall B.K. The permeability of skin and oral mucosa to water and horseradish peroxidase as related to the thickness of the permeability barrier. J. Investig. Dermatol. 1985, 84:176-179.
23. Sudhakar Y., Kuotsu K., Bandyopadhyay A.K. Buccal bioadhesive drug delivery - a promising option for orally less efficient drugs. J. Control. Release 2006, 114:15-40.
24. Li N., Sood S., Wang S., Fang M., Wang P., Sun Z., Yang C.S., Chen X. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of Zileuton and Celecoxib. Clin. Cancer Res. 2005, 11:2089-2096.
25. Zhang H., Zhang J., Streisand J.B. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin. Pharmacokinet. 2002, 41:661-680.
26. Çuburu N., Kweon M.-N., Song J.-H., Hervouet C., Luci C., Sun J.-B., Hofman P., Holmgren J., Anjuère F., Czerkinsky C. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007, 25:8598-8610.
27. Song J.H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.Y., Park S.H., Czerkinsky C., Kweon M.N. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl Acad. Sci. USA 2008, 105:1644-1649.
28. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 2005, 11:S45-S53.
29. Wilson D.R., Torres Lima M., Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005, 60:4-12.
30. Hoogstraate A.J., Cullander C., Nagelkerke J.F., Senel S., Verhoef J.C., Junginger H.E., Bodde H.E. Diffusion rates and transport pathways of florescien isothiocynate (FITC)-labelled model compounds through buccal epithelium. Pharm. Res. 1994, 11:83-89.
31. Sood S., Shiff S.J., Yang C.S., Chen X. Selection of topically applied non-steroidal anti-inflammatory drugs for oral cancer chemoprevention. Oral Oncol. 2005, 41:562-567.
32. Madhav N.V.S., Shakya A.K., Shakya P., Singh K. Orotransmucosal drug delivery systems: a review. J. Control. Release 2009, 140:2-11.
33. Perioli L., Ambrogi V., Giovagnoli S., Ricci M., Blasi P., Rossi C. Mucoadhesive bilayered tablets for buccal sustained release of flurbiprofen. AAPS PharmSciTech 2007, 8:E54.
34. Bensadoun R.J., Daoud J., El Gueddari B., Bastit L., Gourmet R., Rosikon A., Allavena C., Ceruse P., Calais G., Attali P. Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer 2008, 112:204-211.
35. Vazquez J.A., Patton L.L., Epstein J.B., Ramlachan P., Mitha I., Noveljic Z., Fourie J., Conway B., Lalla R.V., Barasch A., Attali P. Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad(R) efficacy and safety (SMiLES). HIV Clin. Trials 2010, 11:186-196.
36. Bernstein G. Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin. Drug Deliv. 2008, 5:1047-1055.
37. Modi P., Mihic M., Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist system. Diab. Metab. Res. Rev. 2002, 18(Suppl. 1):S38-S42.
38. Oh C.K., Ritschel W.A. Biopharmaceutic aspects of buccal absorption of insulin. Methods Find. Exp. Clin. Pharmacol. 1990, 12:205-212.
39. Oh C.K., Ritschel W.A. Absorption characteristics of insulin through the buccal mucosa. Methods Find. Exp. Clin. Pharmacol. 1990, 12:275-279.
40. Autio-Gold J. The role of chlorhexidine in caries prevention. Oper. Dent. 2008, 33:710-716.
41. Bonito A.J., Lux L., Lohr K.N. Impact of local adjuncts to scaling and root planing in periodontal disease therapy: a systematic review. J. Periodontol. 2005, 76:1227-1236.
42. Elad S., Wexler A., Garfunkel A.A., Shapira M.Y., Bitan M., Or R. Oral candidiasis prevention in transplantation patients: a comparative study. Clin. Transplant. 2006, 20:318-324.
43. Cousido M.C., Tomás Carmona I., García-Caballero L., Limeres J., Alvarez M., Diz P. In vivo substantivity of 0.12% and 0.2% chlorhexidine mouthrinses on salivary bacteria. Clin. Oral Investig. 2010, 14:397-402.
44. Tenovuo J. Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia: efficacy and safety. Oral Dis. 2002, 8:23-29.
45. Battino M., Ferreiro M.S., Fattorini D., Bullon P. In vitro antioxidant activities of mouthrinses and their components. J. Clin. Periodontol. 2002, 29:462-467.
46. Claffey N. Essential oil mouthwashes: a key component in oral health management. J. Clin. Periodontol. 2003, 30(Suppl. 5):22-24.
47. Kjaerheim V., Waaler S.M., Kalvik A. Experiments with two-phase plaque-inhibiting mouthrinses. Eur. J. Oral Sci. 1995, 103:179-181.
48. Baqui A.A., Kelley J.I., Jabra-Rizk M.A., Depaola L.G., Falkler W.A., Meiller T.F. In vitro effect of oral antiseptics on human immunodeficiency virus-1 and herpes simplex virus type 1. J. Clin. Periodontol. 2001, 28:610-616.
49. Meiller T.F., Silva A., Ferreira S.M., Jabra-Rizk M.A., Kelley J.I., DePaola L.G. Efficacy of Listerine antiseptic in reducing viral contamination of saliva. J. Clin. Periodontol. 2005, 32:341-346.
50. Utsman R.A., Epstein J.B., Elad S. Budesonide for local therapy of complex oral mucosal immune-mediated inflammatory diseases: case reports. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2008, 106:e11-e17.
51. Gonzalez-Garcia A., Diniz-Freitas M., Gandara-Vila P., Blanco-Carrion A., Garcia-Garcia A., Gandara-Rey J. Triamcinolone acetonide mouth rinses for treatment of erosive oral lichen planus: efficacy and risk of fungal over-infection. Oral Dis. 2006, 12:559-565.
52. Gorsky M., Epstein J., Raviv A., Yaniv R., Truelove E. Topical minocycline for managing symptoms of recurrent aphthous stomatitis. Spec. Care Dent. 2008, 28:27-31.
53. Gorsky M., Epstein J., Rabenstein S., Elishoov H., Yarom N. Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol. Online J. 2007, 13:1.
54. Peppas N.A., Sahlin J.J. Hydrogels as mucoadhesive and bioadhesive materials: a review. Biomaterials 1996, 17:1553-1561.
55. Alsarra I.A., Alanazi F.K., Mahrous G.M., Abdel Rahman A.A., Al Hezaimi K.A. Clinical evaluation of novel buccoadhesive film containing ketorolac in dental and post-oral surgery pain management. Pharmazie 2007, 62:773-778.
56. El-Samaligy M.S., Yahia S.A., Basalious E.B. Formulation and evaluation of diclofenac sodium buccoadhesive discs. Int. J. Pharm. 2004, 286:27-39.
57. Anlar S., Capan Y., Guven O., Gogus A., Dalkara T., Hincal A.A. Formulation and in vitro-in vivo evaluation of buccoadhesive morphine sulfate tablets. Pharm. Res. 1994, 11:231-236.
58. Ikinci G., Capan Y., Senel S., Alaaddinoglu E., Dalkara T., Hincal A.A. In vitro/in vivo studies on a buccal bioadhesive tablet formulation of carbamazepine. Pharmazie 2000, 55:762-765.
59. Save T., Shah M.U., Ghamande A.R., Venkitachalam P. Comparative study of buccoadhesive formulations and sublingual capsules of nifedipine. J. Pharm. Pharmacol. 1994, 46:192-195.
60. Varshosaz J., Dehghan Z. Development and characterization of buccoadhesive nifedipine tablets. Eur. J. Pharm. Biopharm. 2002, 54:135-141.
61. Charde S., Mudgal M., Kumar L., Saha R. Development and evaluation of buccoadhesive controlled release tablets of lercanidipine. AAPS PharmSciTech 2008, 9:182-190.
62. Mohammed F.A., Khedr H. Preparation and in vitro/in vivo evaluation of the buccal bioadhesive properties of slow-release tablets containing miconazole nitrate. Drug Dev. Ind. Pharm. 2003, 29:321-337.
63. Ali J., Khar R.K., Ahuja A. Formulation and characterisation of a buccoadhesive erodible tablet for the treatment of oral lesions. Pharmazie 1998, 53:329-334.
64. Innocenti M., Moscatelli G., Lopez S. Efficacy of gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study. J. Pain Symptom Manage. 2002, 24:456-457.
65. Erjavec V., Pavlica Z., Sentjurc M., Petelin M. In vivo study of liposomes as drug carriers to oral mucosa using EPR oximetry. Int. J. Pharm. 2006, 307:1-8.
66. Campisi G., Giandalia G., De Caro V., Di Liberto C., Arico P., Giannola L.I. A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus. A Phase IV, randomized, observer-blinded, parallel group clinical trial. Br. J. Dermatol. 2004, 150:984-990.
67. Khandwala A., Van Inwegen R.G., Alfano M.C. 5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: I. Clinical demonstration of acceleration of healing and resolution of pain. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1997, 83:222-230.
68. Ortega K.L., Rezende N.P., Araujo N.S., Magalhaes M.H. Effect of a topical antimicrobial paste on healing after extraction of molars in HIV positive patients: randomised controlled clinical trial. Br. J. Oral Maxillofac. Surg. 2007, 45:27-29.
69. Kockisch S., Rees G.D., Tsibouklis J., Smart J.D. Mucoadhesive, triclosan-loaded polymer microspheres for application to the oral cavity: preparation and controlled release characteristics. Eur. J. Pharm. Biopharm. 2005, 59:207-216.
70. Hayashi K., Takada K., Hirasawa M. Clinical and microbiological effects of controlled-release local delivery of minocycline on periodontitis in dogs. Am. J. Vet. Res. 1998, 59:464-467.
71. Allen L.B., Hintz O.J., Wolf S.M., Huffman J.H., Simon L.N., Robins R.K., Sidwell R.W. Effect of 9-beta-d-arabinofuranosylhypoxanthine 5'-monophosphate on genital lesions and encephalitis induced by Herpesvirus hominis type 2 in female mice. J. Infect. Dis. 1976, 133(Suppl.):A178-A183.
72. Gibson J., Halliday J.A., Ewert K., Robertson S. A controlled release pilocarpine buccal insert in the treatment of Sjogren's syndrome. Br. Dent. J. 2007, 202. E17-E17.
73. Karlsmark T., Goodman J.J., Drouault Y., Lufrano L., Pledger G.W. Randomized clinical study comparing Compeed cold sore patch to acyclovir cream 5% in the treatment of herpes simplex labialis. J. Eur. Acad. Dermatol. Venereol. 2008, 22:1184-1192.
74. IntelGenxCorp. Quick Release Wafer Technology. VERSAFILM 2006, Intelgenx Corp.
75. Harrington K.J., Nutting C.M., Pandha H.S. Gene therapy for head and neck cancer. Cancer Metastasis Rev. 2005, 24:147-164.
76. Neves S., Faneca H., Bertin S., Konopka K., Duzgunes N., Pierrefite-Carle V., Simoes S., Pedroso de Lima M.C. Transferrin lipoplex-mediated suicide gene therapy of oral squamous cell carcinoma in an immunocompetent murine model and mechanisms involved in the antitumoral response. Cancer Gene Ther. 2009, 16:91-101.
77. Wollenberg B., Lang S., Schmitt B., Kastenbauer E., Zeidler R. In vitro studies of liposome-mediated gene transfer into head and neck cancer cell lines. Eur. Arch. Otorhinolaryngol. 1997, 254(Suppl. 1):S130-S132.
78. Hamstra D.A., Rice D.J., Pu A., Oyedijo D., Ross B.D., Rehemtulla A. Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model. Radiat. Res. 1999, 152:499-507.
79. Greish K., Frandsen J., Scharff S., Gustafson J., Cappello J., Li D., O'Malley B.W., Ghandehari H. Silk-elastinlike protein polymers improve the efficacy of adenovirus thymidine kinase enzyme prodrug therapy of head and neck tumors. J. Gene Med. 2010, 12:572-579.
80. Dachs G.U., Tupper J., Tozer G.M. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005, 16:349-359.
81. Thomas S.M., Grandis J.R. The current state of head and neck cancer gene therapy. Hum. Gene Ther. 2009, 20:1565-1575.
82. Baum B.J., Adriaansen J., Cotrim A.P., Goldsmith C.M., Perez P., Qi S., Rowzee A.M., Zheng C. Gene therapy of salivary diseases. Methods Mol. Biol. 2010, 666:3-20.
83. Cotrim A.P., Mineshiba F., Sugito T., Samuni Y., Baum B.J. Salivary gland gene therapy. Dent. Clin. North Am. 2006, 50:157-173. vii.
84. Voutetakis A., Bossis I., Kok M.R., Zhang W., Wang J., Cotrim A.P., Zheng C., Chiorini J.A., Nieman L.K., Baum B.J. Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders. J. Endocrinol. 2005, 185:363-372.
85. Xi S., Grandis J.R. Gene therapy for the treatment of oral squamous cell carcinoma. J. Dent. Res. 2003, 82:11-16.
86. Zhang S., Li Y., Li L., Zhang Y., Gao N., Zhang Z., Zhao H. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia. J. Oral Maxillofac. Surg. 2009, 67:1074-1082.
87. Cirelli J.A., Park C.H., MacKool K., Taba M., Lustig K.H., Burstein H., Giannobile W.V. AAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression. Gene Ther. 2009, 16:426-436.
88. Chen R., Chiba M., Mori S., Fukumoto M., Kodama T. Periodontal gene transfer by ultrasound and nano/microbubbles. J. Dent. Res. 2009, 88:1008-1013.
89. Lin Z., Sugai J.V., Jin Q., Chandler L.A., Giannobile W.V. Platelet-derived growth factor-B gene delivery sustains gingival fibroblast signal transduction. J. Periodontal Res. 2008, 43:440-449.
90. Tan Z., Zhao Q., Gong P., Wu Y., Wei N., Yuan Q., Wang C., Liao D., Tang H. Research on promoting periodontal regeneration with human basic fibroblast growth factor-modified bone marrow mesenchymal stromal cell gene therapy. Cytotherapy 2009, 11:317-325.
91. Chang P.C., Seol Y.J., Cirelli J.A., Pellegrini G., Jin Q., Franco L.M., Goldstein S.A., Chandler L.A., Sosnowski B., Giannobile W.V. PDGF-B gene therapy accelerates bone engineering and oral implant osseointegration. Gene Ther. 2009, 10:10.
92. Chang P.C., Cirelli J.A., Jin Q., Seol Y.J., Sugai J.V., D'Silva N.J., Danciu T.E., Chandler L.A., Sosnowski B.A., Giannobile W.V. Adenovirus encoding human platelet-derived growth factor-B delivered to alveolar bone defects exhibits safety and biodistribution profiles favorable for clinical use. Hum. Gene Ther. 2009, 20:486-496.
93. Koh J.T., Ge C., Zhao M., Wang Z., Krebsbach P.H., Zhao Z., Franceschi R.T. Use of a stringent dimerizer-regulated gene expression system for controlled BMP2 delivery. Mol. Ther. 2006, 14:684-691.
94. Shillitoe E. Gene therapy: the end of the rainbow?. Head Neck Oncol. 2009, 1:7.
95. Walther W., Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000, 60:249-271.
96. Williams R.S., Johnston S.A., Riedy M., DeVit M.J., McElligott S.G., Sanford J.C. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles 1991, 2726-2730.
97. Yu J.N., Ma S.F., Miao D.Q., Tan X.W., Liu X.Y., Lu J.H., Tan J.H. Effects of cell cycle status on the efficiency of liposome-mediated gene transfection in mouse fetal fibroblasts. J. Reprod. Dev. 2006, 52:373-382.
98. Neumann E., Schaefer-Ridder M., Wang Y., Hofschneider P.H. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J. 1982, 1:841-845.
99. Graham F.L., van der Eb A.J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973, 52:456-467.
100. Lomas H., Canton I., MacNeil S., Du J., Armes S.P.A., Ryan A.J., Lewis A.L., Battaglia G. Biomimetic pH sensitive olymersomes for efficient DNA encapsulation and delivery. Adv. Mater. 2007, 19:4238-4243.
101. Palermo A., Napoli N., Manfrini S., Lauria A., Stollo R., Pozzilli P. Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral study. Diab. Obes. Metab. 2011, 13:42-46.
102. Oh Y., Varmanen P., Han X.Y., Bennett G., Xu Z., Lu T., Palva A. Lactobacillus plantarum for oral peptide delivery. Oral Microbiol. Immunol. 2007, 22:140-144.
103. Hoogstraate A.J., Senel S., Cullander C., Verhoef J., Junginger H.E., Bodde H.E. Effects of bile salts on transport rates and routes of FITC-labelled compounds across porcine buccal epithelium in vivo. J. Control. Release 1996, 40:211-221.
104. Joseph A.N., Barry L.R., Barrie C.F. Enhanced buccal mucosal retention and reduced buccal permeability of estradiol in the presence of padimate O and Azone®: a mechanistic study. J. Control. Release 2005, 94:873-882.
105. Langoth N., Kahlbacher H., Schoffmann G., Schmerold I., Schuh M., Franz S., Kurka P., Bernkop-Schnurch A. Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system. Pharm. Res. 2006, 23:573-579.
106. de la Fuente M., Csaba N., Garcia-Fuentes M., Alonso M.J. Nanoparticles as protein and gene carriers to mucosal surfaces. Nanomedicine 2008, 3:845-857.
107. Bangham A.D. A correlation between surface charge and coagulant action of phospholipids. Nature 1961, 192:1197-1198.
108. Discher B.M., Won Y., Ege D.S., Lee J.C.M., Bates F.S., Discher D.E., Hammer D.A. Polymersomes: tough vesicles made from diblock copolymers. Science 1999, 284:1143-1146.
109. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2:347-360.
110. Lasic D.D. Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo. J. Control. Release 1997, 48:203-222.
111. Lasic D.D., Papahadjopoulos D. Medical Applications of Liposomes 1998, Elsevier, Amsterdam.
112. Harsanyi B.B., Hilchie J.C., Mezei M. Liposomes as drug carriers for oral ulcers. J. Dent. Res. 1986, 65:1133-1141.
113. Discher D.E., Ortiz V., Srinivas G., Klein M.L., Kim Y., Christian D., Cai S., Photos P., Ahmed F. Emerging applications of polymersomes in delivery: from molecular dynamics to shrinkage of tumors. Prog. Polym. Sci. 2007, 32:838-857.
114. Lasic D.D. Sterically stabilized vesicles. Angew. Chem. Int. Ed. 1994, 33:1685-1698.
115. Discher D.E., Eisenberg A. Polymer vesicles. Science 2002, 297:967-973.
116. Hearnden V., Lomas H., MacNeil S., Thornhill M., Murdoch C., Lewis A.L., Madsen J., Blanazs A., Armes S.P., Battaglia G. Diffusion studies of nanometer polymersomes across tissue engineered human oral mucosa. Pharm. Res. 2009, 26:1718-1728.
117. Hamakawa H., Nakashiro K., Sumida T., Shintani S., Myers J.N., Takes R.P., Rinaldo A., Ferlito A. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 2008, 30:800-809.
118. Nicholson R.I., Gee J.M.W., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 2001, 37:9-15.
119. Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999, 59:1935-1940.
120. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H.R., Cupissol D., Peyrade F., Benasso M., Vynnychenko I., De Raucourt D., Bokemeyer C., Schueler A., Amellal N., Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008, 359:1116-1127.
121. Lorch J.H., Posner M.R., Wirth L.J., Haddad R.I. Seeking alternative biological therapies: the future of targeted molecular treatment. Oral Oncol. 2009, 45:447-453.
122. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
123. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 1986, 46:6387-6392.
124. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 2009, 71:409-419.
125. Gabizon A.A., Shmeeda H., Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 2006, 16:175-183.
126. Wang M., Thanou M. Targeting nanoparticles to cancer. Pharmacol. Res. 2010, 62:90-99.
127. Hammer D.A., Robbins G.P., Haun J.B., Lin J.J., Qi W., Smith L.A., Ghoroghchian P.P., Therien M.J., Bates F.S. Leuko-polymersomes. Faraday Discuss. 2008, 139:129-141. discussion 213-128, 419-120.
128. Al-Hazmi N., Thomas G.J., Speight P.M., Whawell S.A. The 120kDa cell-binding fragment of fibronectin up-regulates migration of alphavbeta6-expressing cells by increasing matrix metalloproteinase-2 and -9 secretion. Eur. J. Oral Sci. 2007, 115:454-458.